Baumann will become a member of the Executive Board and will be responsible for research, preclinical and clinical development, approval and Mologen’s clinical strategy. Until his switch to Mologen, Baumann will continue working as CMO for the biotech German company Noxxon Pharma AG. Prior to joining Noxxon in February 2011, Baumann was Chief Scientific Officer of Focus Clinical Drug Development GmbH and previously active in various research and development positions at Roche and Boehringer Mannheim.